Post
Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
New Phase IIb data suggests a combination therapy of Akero Therapeutics’s efruxifermin and Novo Nordisk’s Ozempic (semaglutide) can reduce liver …
ASCO 2023: Janssen present positive follow-up data for first in line therapy for lung cancer
Janssen Pharmaceuticals has presented long-term results from its CHRYSALIS study, which showed the combination of Rybrevant (amivantamab-vmjw) and lazertinib, was …
ASCO 2020: Janssen reports positive results for Talquetamab in Multiple myeloma
Johnson & Johnson (J&J) has reported results from its Phase I studies investigating talquetamab as a monotherapy and in combination …
ASCO 2023: Research backs chemo-only approach for some rectal cancer patients
Results unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that some patients with locally advanced …
Servier’s Phase III INDIGO trial of vorasidenib meets endpoints
Servier has reported that the Phase III INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 isocitrate …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
AstraZeneca reports positive results from ADAURA Phase III trial
AstraZeneca has reported positive results from the ADAURA Phase III trial of Tagrisso (osimertinib) in the adjuvant treatment of patients …
Vivavision’s Phase IIa study of ophthalmic solution meets primary endpoints
Vivavision Biotech has reported that its Phase IIa first in human study of VVN539 Ophthalmic Solution in the US has met …
Chimeric launches Phase IB trial of glioblastoma multiforme therapy
Chimeric Therapeutics has launched a new Phase IB clinical trial of CHM 1101 (CLXT CAR T) cell therapy to treat …
Elicio reports positive interim clinical data of cancer immunotherapy study
Elicio Therapeutics has reported positive interim clinical data from its ongoing Phase I AMPLIFY-201 study evaluating its cancer immunotherapy, ELI-002, …
BioInvent receives IND approval for study of anti-TNFR2 antibody
BioInvent International has received investigational new drug (IND) approval to initiate a Phase I/IIa study of BI-1910. Compared to BioInvent’s BI-1808 …
Leading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, …
First patient enrolled in pulmonary hypertension reduction device study
Paris-based Gradient Denervation Technologies has performed the first procedure in its first-in-human clinical study for a pulmonary hypertension device. The …
Innovent and Merck to carry out cancer combination therapy trial
Innovent Biologics and Merck have entered a clinical trial collaboration and supply agreement for the combination therapy of IBI351 (GFH925) …
YS Biopharma receives approval for vaccine trial in Philippines
The Food and Drug Administration (FDA) of the Philippines has given approval to biopharmaceutical firm YS Biopharma to begin a …
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts …